Table 2.
Demographic, clinical, and biological characteristics of the pediatric and adult populations of our series.
| Age (Y) | Sex | Height (SD) | Weight (SD) | BMI (SD) | T1D family history | CD family history | HbA1c (%) | Age at T1D onset (Y) | T1D duration (Y) | Daily insulin dose (IU/Kg) | Known microvascular complications |
Known macrovascular complications |
Insulin type prescribed | Insulin regimen | Severe hypoglycemia episodes | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Children <15 years (n = 167) | 9 ± 3.7 | 48.5% F | −0.57 ± 1.2 | −0.36 ± 1.1 | −0.13 ± 1.3 | 19.2% | 4.2% | 9.6 ± 2.4 | 6 ± 3.5 | 3.1 ± 2.9 | 0.75 ± 0.2 | 0% | 0% | HI (89%) AN (10.8%) | 2 INJ (91.6%) BB (7.8%) 3 INJ (0.6%) | <1/M (93.4%) 1–4/M (6.6%) |
| Adults ≥15 years (n = 109) | 21 ± 6.6 | 57.8% F | NA | NA | NA | 24.8% | 5.5% | 10.1 ± 2.7 | 12 ± 7.3 | 8.8 ± 6.2 | 0.9 ± 0.3 | 12.8% | 1.8% | HI (77.1%) AN (21.1%) | 2 INJ (49.5%) 3 INJ (27.5%) BB (11.9%) FI (11%) | <1/M (95.4%) 1–4/M (1.8%) >1/W (2.8%) |
HI: human insulin; AN: analogues; INJ: injections; BB: basal bolus; FI: functional insulin therapy; M: month; W: week; NA: not applicable.